Share on LinkedInShare on LinkedIn

ARTICLE · 01 AUGUST 2025

DOJ And FTC Host Second Session On Structural And Regulatory Impediments To Drug Competition

Sheppard
Sheppard
Contributor
Sheppard

Sheppard

Businesses turn to Sheppard to deliver sophisticated counsel to help clients move ahead. With more...

View firm profile
Explore more from Sheppard

On July 24, 2025, the Federal Trade Commission ("FTC") and the U.S. Department of Justice ("DOJ") convened the second of three public listening sessions aimed at identifying barriers...

United StatesAntitrust/Competition Law

On July 24, 2025, the Federal Trade Commission ("FTC") and the U.S. Department of Justice ("DOJ") convened the second of three public listening sessions aimed at identifying barriers to drug price competition in the U.S. healthcare system. The session is part of a broader policy push under Executive Order 14273, "Lowering Drug Prices by Once Again Putting Americans First," which mandates a coordinated federal effort to investigate and dismantle anticompetitive practices within the pharmaceutical sector, with the overarching goal of reducing prescription drug costs for Americans. The July 24th session concentrated on issues relating to formulary design, benefit management, and the misuse of regulatory mechanisms that may restrict or delay generic and biosimilar market entry.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from